Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent

References

• Parmar S, Tallman MS. Acute promyelocytic leukaemia: a review. Expert Opin Pharmacother 2003;4:1379–92
   PubMed Web of Science ®Google Scholar
• Ohno R, Asou N, Ohnishi K, et al. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003;17:1454–63
   PubMed Web of Science ®Google Scholar
• Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Engl J Med 1998;339:1341–48
   Google Scholar
• Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852–60
   PubMed Web of Science ®Google Scholar
• Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003;97:2218–24
   Google Scholar
• Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-trans retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003;21:2326–34
   PubMed Web of Science ®Google Scholar
• Zhang P, Wang SY, Hu L, et al. Arsenic trioxide-treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;17:58–60
   Google Scholar
• Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89: 3354–60
   Google Scholar
• Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315–24
   PubMed Web of Science ®Google Scholar
• Mathews V, Balasubramanian P, Shaji VR, et al. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 2002;70:292–9
   PubMed Web of Science ®Google Scholar
• Oliva C, Kirkhart B, Maxon MS, Earhart R. Safety experience with TRISENOX® (arsenic trioxide) injection [abstract]. Hematol J 2004;5(Suppl2):180
   Google Scholar
• Lehmann S, Bengtzen S, Paul A, Christensson B, Paul C. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. Eur J Haematol 2001;66: 357–64
   Google Scholar
• Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia cell lines: induction of apoptosis and inhibition of proliferation. Br J Hematol 2002;116: 555–63
   PubMed Web of Science ®Google Scholar
• Kajiguchi T, Yamamoto K, Hossain K, et al. Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. Leukemia 2003;17:2189–95
   PubMed Web of Science ®Google Scholar
• Zhu J, Okumura H, Ohtake S, Nakamura S, Nakao S. Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system. Oncol Rep 2003;10: 705–9
   Google Scholar
• Anderson KC, Boise LH, Louie R, Waxman S. Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 2002;8:12–24
   PubMed Web of Science ®Google Scholar
• Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 2002;8:566–72
   Google Scholar
• Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002;1:851–60
   PubMed Web of Science ®Google Scholar
• List AF. New approaches to the treatment of myelodysplasia. Oncologist 2002;7(Suppl 1):39–49
   PubMedGoogle Scholar
• Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893–903
   PubMedGoogle Scholar
• Tong H, Lin M. Demethylation of p15INK4B gene in myelodysplasia cells induced by arsenic trioxide [abstract]. Blood 2002;100(11):375a
   PubMed Web of Science ®Google Scholar
• Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 2003;63:2103–8
   Google Scholar
• Li X, Ding X, Adrian TE. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas 2003;27:174–9
   Google Scholar
• Park WH, Cho HY, Jung WC, et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 2003;300:230–5
   PubMed Web of Science ®Google Scholar
• Wang SS, Zhang T, Wang XL, Hong L, Qi RH. Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxicity. World J Gastroenterol 2003;9:930–5
   Google Scholar
• Bahlis NJ, McCafferty-Grad J, Jordan-McMurray I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8:3658–68
   PubMed Web of Science ®Google Scholar
• Munshi NC, Tricot G, Desikan R, et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002;16:1835–7
   PubMed Web of Science ®Google Scholar
• Berenson JR, Yang H, Vescio R, et al. Preliminary findings in a phase 1/2 study of TRISENOX (arsenic trioxide) twice weekly in patients with advanced multiple myeloma [abstract]. Hematol J 2003;4(Suppl 2):163
   PubMedGoogle Scholar
• Berenson JR. A phase I/II multicenter, safety and efficacy study of combination treatment with melphalan, arsenic and vitamin C (ascorbic acid) (MAC) in patients with refractory or relapsed multiple myeloma [abstract]. Hematol J 2004;5(Suppl 2):128
   Google Scholar
• Vey N, Dreyfus F, Guerci A, et al. TRISENOX (arsenic trioxide) in patients with myelodysplastic syndromes: preliminary results of a phase I/II study [abstract]. Hematol J 2004;5(Suppl 2):161
   PubMedGoogle Scholar
• List A, Schiller G, Mason J, Douer D, Ellison R. Arsenic trioxide in patients with myelodysplastic syndromes: preliminary findings in a phase II study [abstract]. Proc Am Soc Clin Oncol 2004;23: 559
   Google Scholar
• Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004;125:470–6
   PubMed Web of Science ®Google Scholar
• Chen CQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: I. As₂O₃ exerts dose-dependent dual effects on APL cells. Blood 1997; 89:3345–53
   Google Scholar
• Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90:124–33
   PubMed Web of Science ®Google Scholar
• Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268–77
   PubMed Web of Science ®Google Scholar
• Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL. Blood 2000;95:1014–22
   PubMed Web of Science ®Google Scholar
• Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102–11
   Google Scholar
• Kitamura K, Minami Y, Yamamoto, K, et al. Involvement of Cd95-independent caspase 8 activation in arsenic trioxide- induced apoptosis. Leukemia 2000;14:1743–50
   PubMed Web of Science ®Google Scholar
• Grad JM, Bahlis NJ, Reis A, et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001;98:805–13
   PubMed Web of Science ®Google Scholar
• Park JW, Choi YJ, Jang MA, et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun 2001;286:726–34
   PubMed Web of Science ®Google Scholar
• McCafferty-Grad J, Bahlis NJ, Krett N, et al. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther 2003;2:1155–64
   Google Scholar
• Korper S, Nolte F, Thiel E, Schrezenmeier H, Rojewski MT. The role of mitochondrial targeting in arsenic trioxide-induced apoptosis in myeloid cell lines. Br J Haematol 2004;124:186–9
   Google Scholar
• Huang C, Ma WY, Li J, Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 1999;59:3053–58
   PubMed Web of Science ®Google Scholar
• Davison K, Mann KK, Waxman S, Miller WH. JNK activation is a mediator or arsenic-trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004;103:3496–502
   PubMed Web of Science ®Google Scholar
• Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052–61
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shen WL. Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide. Cell Biol Int 2003;27:953–8
   PubMed Web of Science ®Google Scholar
• Chou WC, Hawkins AL, Barrett JF, Griffin CA, Dang CV. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 2001;108:1541–47
   Google Scholar
• Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase. J Biol Chem 2000;275:36062–6
   PubMed Web of Science ®Google Scholar
• Mathas S, Lietz A, Janz M, et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003;102:1028–34
   PubMed Web of Science ®Google Scholar
• La Rosée P, Johnson K, O’Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002;30:729–37
   Google Scholar
• Nimmanapalli R, Bali P, O’Bryan E, et al. Arsenic trioxide inhibits translation of mRNA of Bcr-Abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res 2003;63:7950–8
   Google Scholar
• Roboz GJ., Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000;96:1525–30
   PubMed Web of Science ®Google Scholar
• Shen Y, Shen ZX, Yan H, et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 2001;15:735–41
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen GQ, Shen ZX, et al. Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol 2002;39 (Suppl 1):22–6
   PubMedGoogle Scholar
• Remick S. Pharmacokinetics of arsenic trioxide in cancer patients with renal dysfunction: preliminary results of a phase I clinical study [abstract]. Proc Am Soc Clin Oncol 2004;23:131
   Google Scholar
• Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103;1237–43
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA Cooperative Groups. Blood 2000;96:1247–53
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192–1200
   Google Scholar
• Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004;101:5328–35
   PubMed Web of Science ®Google Scholar
• Wang G, Li W, Cui J, et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol 2004;22:63–71
   PubMed Web of Science ®Google Scholar
• Estey EH, Faderl S, Giles F, et al. All-trans retinoic acid plus arsenic trioxide to minimize or eliminate chemotherapy in untreated APL [abstract]. Blood 102(11):618a
   Google Scholar
• Child JA, Morgan GJ, Davies FE, et al.; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New Engl J Med 2003;348:1875–83
   Google Scholar
• Attal M, Harousseau JL, Facon T, et al.; InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. New Engl J Med 2003;349:2495–502
   Google Scholar
• Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000;60:3065–71
   PubMed Web of Science ®Google Scholar
• Rousselot P, Larghero J, Labaume S, et al. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol 2004;72:166–71
   PubMed Web of Science ®Google Scholar
• Hussein M, Reed J, Karam MA, et al. Clinical experience with Trisenox® (arsenic trioxide) as a single-agent and in combination with ascorbic acid and dexamethasone [abstract]. Hematol J 2003;4(Suppl 2):166
   Google Scholar
• Raza A, Buonamici S, Lisak L, et al. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 2004;28:791–803
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group of standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671–4
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med 2002;346:645–52
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190–6
   PubMed Web of Science ®Google Scholar
• Puccetti E, Guller S, Orleth A, et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000;60:3409–13
   PubMed Web of Science ®Google Scholar
• La Rosée P, Johnson K, Corbin AS, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 2004;103:208–15
   Google Scholar
• Mauro MJ, Deininger MW, O’Dwyer ME, et al. Phase I/II study of arsenic trioxide (Trisenox) in combination with imatinib mesylate (Gleevec) in patients with Gleevec-resistant chronic myelogenous leukemia in chronic phase [abstract]. Blood 2002;100:781a
   Google Scholar
• Parmar S, Rundhaugen LM, Boehlke L, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 2004;28:909–19
   PubMed Web of Science ®Google Scholar
• Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukemia? Br J Haematol 2001;112:783–6
   Google Scholar